Etamycin | 102646-56-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: Etamycin
• 英文别名: 3-hydroxy-N-[24-hydroxy-7,11,13,17,20-pentamethyl-16-(3-methylbutan-2-yl)-3-(2-methylpropyl)-2,5,9,12,15,18,21-heptaoxo-10-phenyl-8-oxa-1,4,11,14,17,20-hexazabicyclo[20.3.0]pentacosan-6-yl]pyridine-2-carboxamide
• CAS: 102646-56-0
• 化学式: C₄₄H₆₂N₈O₁₁
• 分子量: 879.0
• InChiKey: SATIISJKSAELDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  63
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  248
• 氢给体数：
  5
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  Neoviridogrisein IV 、 Etamycin 、 (1S,9R,11S,12Z,14Z,19Z,22R)-9,11-dihydroxy-22-methyl-6,23-dioxa-26-thia-2,17,27-triazatricyclo[17.5.2.14,7]heptacosa-4,7(27),12,14,19-pentaene-3,18,24-trione 在 甲醇 作用下， 以obtained in Example 5的产率得到N-苯基-N-甲基甘氨酸
  参考文献：
  名称：

  Streptomyces culture

  摘要：

  一组新型的脱氨肽类抗生素，新绿霉素I，II和III，是通过Streptomyces sp. P8648（FERM-P 3562; ATCC 31289）的发酵生产而来。这些抗生素对革兰氏阳性菌和支原体非常活跃。

  公开号：

  US04355112A1

文献信息

• Streptogramin antibiotics
  申请人：Koteva Kalinka

  公开号：US20050272646A1

  公开（公告）日：2005-12-08

  Disclosed is a cyclic peptide antibiotic in which an enzyme-sensitive bond is replaced by an enzyme-resistant bond.

  揭示了一种循环肽抗生素，其中一种酶敏感键被一种酶抗性键取代。
• Streptogramin derivatives, their preparation and compositions containing them
  申请人：——

  公开号：US20030162962A1

  公开（公告）日：2003-08-28

  The present invention relates to group A streptogramin derivatives of general formula (I) and processes for preparing the same: 1 which has particularly advantageous antibacterial activity.

  本发明涉及一般式(I)的A群链球菌素衍生物及其制备方法，具有特别优异的抗菌活性。
• Pharmaceutical preparation, method for its production as well as its use
  申请人：Heraeus Kulzer GmbH & Co. KG

  公开号：US20040067253A1

  公开（公告）日：2004-04-08

  The invention relates to hardly soluble antiphlogistic salts and antiphlogistic-antibiotic pharmaceutical preparations and their use. The hardly water soluble antiphlogistic antibiotics salts have as their cationic component one of the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicyline, oxytetracycline and rolitetracycline and as their anionic component one of the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate. The antiphlogistic antibiotics salts are used in pharmaceutical preparations as controlled-release antibiotic/antibiotics drugs. The invention describes antiphlogistic-antibiotic pharmaceutical preparations for which mixtures in the solid state of aggregation are used, which are composed of an easily water soluble salt of gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicycline, oxytetracycline and/or rolitetracycline and at least one easily water soluble salt of ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and/or triamcinolone-21-sulfate and at least one inorganic and/or organic pharmaceutical adjuvant and which are used as permanent or temporary implants in the form of tablets and/or molded bodies.

  本发明涉及难溶性抗炎盐和抗炎抗生素制剂及其使用。难水溶性抗炎抗生素盐的阳离子组分为庆大霉素、林可霉素、新霉素、链霉素、四环素、多西环素、氧四环素和罗利四环素之一，阴离子组分为布洛芬、萘普生、消炎症、地塞米松-21-磷酸酯、地塞米松-21-硫酸酯、曲安奈德-21-磷酸酯和曲安奈德-21-硫酸酯之一。抗炎抗生素盐用作控制释放抗生素药物的制剂。本发明还描述了抗炎抗生素制剂，其中使用固态混合物，该混合物由庆大霉素、林可霉素、新霉素、链霉素、四环素、多西环素、氧四环素和/或罗利四环素的易水溶性盐和布洛芬、萘普生、消炎症、地塞米松-21-磷酸酯、地塞米松-21-硫酸酯、曲安奈德-21-磷酸酯和/或曲安奈德-21-硫酸酯的至少一个易水溶性盐和至少一个无机和/或有机制药助剂组成，并用作以片剂和/或成型体形式的永久或临时植入物。
• Lactation improvement method
  申请人：ELI LILLY AND COMPANY

  公开号：EP0063490A1

  公开（公告）日：1982-10-27

  Milk production in lactating ruminants is improved by the oral administration of an antibiotic selected from the virginiamycin or elfamycin families of antibiotics.

  通过口服一种选自维吉尼霉素或埃法霉素抗生素家族的抗生素，可提高泌乳反刍动物的产奶量。
• Improved penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0129284A2

  公开（公告）日：1984-12-27

  Improved topical pharmaceutical compositions containing a pharmaceutically-active agent and the penetration enhancing agent 1-dodecylazacycloheptan-2-one are disclosed. This agent is used at selected levels in combination with certain C3-C4 diols or a 1-substituted azacycloalkyl-2-one. This composition provides marked transepidermal and percutaneous delivery of the selected pharmaceutically-active agent. A method of treating certain pathologies and conditions responsive to the selected active, systemically or locally, is also disclosed.

  本发明公开了含有一种药物活性剂和渗透增强剂 1-十二烷基氮杂环庚烷-2-酮的改良外用药物组合物。这种药剂与某些 C3-C4 二醇或 1-取代偶氮环烷基-2-酮结合使用时，可达到选定的水平。这种组合物能明显地经皮和经皮给药。此外，还公开了一种全身或局部治疗对所选活性剂有反应的某些病理和病症的方法。